Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR




The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.

Study Status: Active, not recruiting


Condition Intervention Phase
Drug: NB32
Drug: PBO
Behavioral: Weight Management Program
Phase 3

Verified by Orexigen Therapeutics, Inc May, 2013

Sponsored by: Orexigen Therapeutics, Inc
Information provided by: Orexigen Therapeutics, Inc identifier: NCT01601704

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Beachwood FHC
Beachwood, Ohio 44122
United States

The Cleveland Clinic
Cleveland, Ohio 44195
United States

Cleveland Clinic Willoughby Hills FHC
Willoughby Hills, Ohio 44094
United States

Senior Vice President, Head of Global Development., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site